$TWST

Green Paula sold $2.1M of TWST

Green Paula (SVP of Human Resources) sold 26,137 shares of Twist Bioscience Corp (TWST) at an average of $81.67 ($81.62–$82.17, $2.13M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Green Paula
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Insider open-market sales can be interpreted as mild bearish sentiment, but without additional disclosures (earnings, guidance, litigation, trials, or deals) the trading signal is typically weak.

02

Market read

A $2.13M insider sale was reported, which may cause short-term sentiment noise but lacks fundamental catalysts in the text.

03

What to watch

The article does not state whether the insider’s remaining holdings are large relative to prior grants, nor does it provide context on total insider activity or option exercises that could offset selling.

Relevance 6/10Novelty 3/10Timing: filed June 17, covering trades executed June 15

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience SVP of Human Resources Green Paula sold about $2.13M of TWST shares via open-market transactions on June 15.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction. While the sale size is notable, insider sales are often non-informational and the article provides no accompanying corporate event, guidance change, or regulatory action.

Market effects

Minimal. Insider selling at a single biotech toolmaker is unlikely to reset sector expectations.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan does not necessarily imply negative information; sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs not captured here.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Green Paula

    SVP of Human Resources who sold TWST shares.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.